Koenig Scott 4

What Happened

• Scott Koenig, a director of MacroGenics, reported the conversion/exercise of 21,165 derivative units (code M) on Feb 15, 2026. The filing shows 21,165 shares acquired at $0.00 and a corresponding disposition of 21,165 derivative units at $0.00 — i.e., RSUs were converted into common stock. No cash purchase or open‑market sale is reported in this transaction.

Key Details

• Transaction date: 2026-02-15; Form 4 filed: 2026-02-17 (timely).
• Reported amounts: 21,165 shares acquired (exercise/conversion) at $0.00; 21,165 derivative units disposed at $0.00.
• Shares owned after the transaction: not specified in the provided excerpt — see the full Form 4 for total beneficial ownership.
• Footnotes: F1 notes a Feb 15, 2023 grant of 127,000 RSUs; 84,670 vested earlier and 21,165 vested upon Koenig’s separation on Aug 13, 2025 per his Separation Agreement. F2 clarifies each RSU equals a contingent right to one share of common stock.
• Transaction code M indicates exercise or conversion of a derivative (here, RSUs converting to underlying shares).

Context

• This is a routine conversion of restricted stock units into shares rather than an open‑market buy or sale; it does not by itself signal a directional trade (buy/sell) by the insider. For a complete picture of Koenig’s holdings and any subsequent sales, consult the full Form 4 filing.